奥美拉唑联合法莫替丁与单用雷尼替丁治疗消化性溃疡的疗效比较被引量：6

Comparison of Therapeutic Efficacy of Omeprazole Combined with Famotidine vs.Ranitidine in the Treatment of Peptic Ulcer

原文传递

导出

摘要目的:比较奥美拉唑联合法莫替丁与单用雷尼替丁治疗消化性溃疡的疗效。方法:将我院2009年1月-2010年11月住院的消化性溃疡患者95例随机分为联合治疗组(48例,应用奥美拉唑联合法莫替丁治疗)与雷尼替丁组(47例,单用雷尼替丁治疗),2组均应用左氧氟沙星进行抗菌治疗。2组均随访6个月,观察并比较治疗后2组胃内pH值、幽门螺旋杆菌(Hp)是否根除等指标。结果:与雷尼替丁组比较,联合治疗组抗酸能力强而持久(P<0.05)。经过6个月的随访,联合治疗组Hp清除更彻底(P<0.05)。2组均未见严重不良反应发生。结论:奥美拉唑联合法莫替丁治疗消化道溃疡疗效确切、安全性较好。 OBJECTIVE:To observe therapeutic efficacy of omeprazole combined with famotidine vs.ranitidine in the treatment of peptic ulcer.METHODS:From Jan.2009 to Nov.2010,95 inpatients with peptic ulcer were randomly divided into combined therapy group(48 cases,omeprazole combined with famotidine) and ranitidine group(47 cases,ranitidine).Levofloxacin was used to make antibiotic treatment in 2 groups.All cases were followed up for 6 months.pH in stomach,helicobacter pylori(Hp) eradicated or not and other indicators were compared before and after treatment.RESULTS:After 4 weeks treatment,peptic ulcer symptoms of 2 groups were improved.Compared with ranitidine group,acid resistance capacity of combined therapy group was strong and persistent(P<0.05).After 6 months following-up,Hp was removed completely in combined therapy group(P<0.05).No severe ADR was found in 2 groups.CONCLUSION:Omeprazole combined with famotidine is effective and safe in treatment of peptic ulcer.

作者周越陈燕萍

机构地区金华市中心医院药剂科金华市中心医院消化科

出处《中国药房》 CAS CSCD 2012年第28期2650-2651,共2页 China Pharmacy

关键词奥美拉唑法莫替丁雷尼替丁消化性溃疡 Omeprazole Famotidine Ranitidine Peptic ulcer

分类号 R975.6 [医药卫生—药品] R656.62 [医药卫生—外科学]

引文网络
相关文献

参考文献7

1Roberts DN, Miner PB. Safety aspects and rational use of a naproxen + esomeprazole combination in the treatment of rheumatoid disease[J]. Drug Healthc Patient Saf, 2011,3(3):1.
2黄睿,张弛,黄靓.雷贝拉唑与奥美拉唑治疗幽门螺杆菌阳性消化性溃疡疗效及抑酸作用比较[J].临床和实验医学杂志,2008,7(5):127-128. 被引量：25
3Song KH, Lee YC, Fan DM, et al. Healing effects of re- bamipide and omeprazole in helicobacter pylori-positive gastric ulcer patients after eradication therapy: A random- ized double-blind, multinational, multi-Institutional com- parative study[J]. Digestion, 2011,84 (3) : 221.
4Esplugues JV, Marti-Cabrera M, Ponce J. Safety of pro- ton pump inhibitors[J]. Med Clin(Barc), 2006, 127(20) : 790.
5Song WJ, Kim MH, Lee SM, etal. Two cases ofh(2)-re- ceptor antagonist hypersensitivity and cross-reactivity[J]. Allergy Asthma lmmunol Res, 2011,3 ( 2 ) : 128.
6Reveiz L, Guerrero-Lozano R, Camacho A, et al. Stress ulcer, gastritis, and gastrointestinal bleeding prophylaxis in critically ill pediatric patients: a systematic review[J]. Pediatr Crit Care Med, 2010,11 ( 1 ) : 124.
7Serebrova SIU. The clinical effectiveness of rabeprazole in patients with acid-related gastric and duodenal diseases with various sensitivity of different types of parietal gas- tric cell receptors[J]. Klin Med, 2007,85 (3):61.